The nation of Zimbabwe has declined a significant US health deal valued at 367 million US dollars (£272m) over five years over the United States' request for sensitive biological samples.
This move came to light following a internal memorandum from December was disclosed, which showed President Emmerson Mnangagwa felt the deal was "unbalanced".
A government spokesman later clarified that the United States was requesting biological samples for research and commercial gain but was not willing to guarantee the benefits from any future treatments.
"We are forced to start the challenging and unfortunate process of ending our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the United States had provided more than $1.9bn in health funding to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has urged further negotiations to secure a agreement agreeable to both sides so the country's critical HIV treatment initiative can be sustained.
Wider Background
This development follows a similar situation in Kenya, where a court blocked a similar deal with the US following legal challenges were filed about the safety of citizens' health data.
After returning to the presidency recently, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
The agency had administered assistance for the US government, but Trump argued its spending was "wasteful" and his administration was pursuing government-to-government deals to boost openness and accountability.
According to statements, Sixteen African countries have to date agreed to these new agreements, representing over $18.3bn in committed funds.
Details of the Rejected Deal
The funds for Zimbabwe was intended to funded "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this cooperation could have provided extraordinary advantages for the people of Zimbabwe, particularly the 1.2 million currently receiving antiretroviral therapy through American-funded programmes," the Ambassador added.
However, government spokesperson Nick Mangwana said the proposed deal was "unfair".
"Our nation was requested to share its biological resources and data indefinitely, with no corresponding promise of access to any medical innovations – like new medicines or tests – that could be developed from that shared data," he stated.
"Put simply, our nation would provide the raw materials for medical research with no assurance that the final treatments would be available to our population if a new pandemic arise."
Sovereignty and International Frameworks
Mangwana further said that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one health agreements were undermining systems previously established via the international health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing scheme created to deal with future pandemics.
"This mechanism is designed to guarantee that when a nation contributes its data, the resulting advantages – such as medicines and cures – are shared equitably, not monopolised solely by those with the capability to create them."
These objections regarding the US deal "must not be interpreted as hostility towards the US," he added.
"We welcome continued discussions with our American counterparts on how future collaboration could be structured in a way that honours the sovereignty and interests of each country."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it acknowledged the official position, but suggested that negotiations need to persist given that a large portion of the nation's Aids initiatives relied on international support.
"If specific concerns exist, including those involving data governance or implementation frameworks, these can frequently be addressed via detailed discussion and mutually agreed protections," the group said.
The situation underscores the complex tensions between accepting crucial foreign assistance and safeguarding national sovereignty in an increasingly data-driven world.